Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $20.25

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus rating of “Hold” from the twenty-three ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.4565.

A number of research analysts have issued reports on NTLA shares. New Street Research set a $25.00 target price on Intellia Therapeutics in a research report on Monday, June 15th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Morgan Stanley lifted their price target on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Finally, Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research note on Monday, June 15th.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $15.67 on Friday. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $28.25. The business’s 50-day moving average price is $13.78 and its two-hundred day moving average price is $12.53. The stock has a market cap of $2.19 billion, a PE ratio of -4.43 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the previous year, the business posted ($1.10) earnings per share. As a group, analysts expect that Intellia Therapeutics will post -3.18 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its position in shares of Intellia Therapeutics by 0.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after buying an additional 808 shares during the last quarter. Comerica Bank lifted its position in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Intellia Therapeutics by 36.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares in the last quarter. Wealthfront Advisers LLC lifted its holdings in Intellia Therapeutics by 7.6% during the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock worth $185,000 after purchasing an additional 1,018 shares in the last quarter. Finally, Interchange Capital Partners LLC lifted its holdings in Intellia Therapeutics by 9.7% during the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock worth $202,000 after purchasing an additional 1,030 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.